Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 randomized double-blind placebo-controlled single ascending dose trial of VIS171 in healthy Japanese participants
jRCT2031240741Phase 1Completed
- Sponsor
- Visterra
- Start
- Apr 2025
- Modality
- Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VIS171 in None (4 arms), sponsored by Visterra. Started Apr 2025; status: completed.
02
Drugs
VIS171
Beyond the preview
Go deeper on jRCT2031240741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240741.